# Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Canonical URL: https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-may
Ticker: EXEL
Company: Exelixis
Source: Exelixis
Published: 2026-05-07 20:05 EST
Original Source URL: https://ir.exelixis.com
## Summary

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026:

## Article Body
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026:
## Recent Company News
- 2026-05-30 14:00 EST — [Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026](https://biopharmsignal.com/news/EXEL/exelixis-announces-results-from-subgroup-analysis-of-phase-3-cabinet-pivotal-trial-evaluating-cabometyxr-cabozantinib-in-non-functional-and-functional-neuroendocrine-tumors-at-asco-2026) — Source: Exelixis
- 2026-05-27 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-june) — Source: Exelixis
- 2026-05-21 21:00 EST — [Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types](https://biopharmsignal.com/news/EXEL/exelixis-announces-presentations-at-asco-2026-highlighting-ongoing-studies-in-diverse-tumor-types) — Source: Exelixis
- 2026-05-19 12:00 EST — [Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer](https://biopharmsignal.com/news/EXEL/exelixis-announces-clinical-development-collaboration-with-merck-for-phase-3-stellar-316-pivotal-trial-for-patients-with-colorectal-cancer) — Source: Exelixis
- 2026-05-07 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-may) — Source: Exelixis
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)